Cargando…
Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study
OBJECTIVES: Although chemotherapy-induced congestive heart failure (CHF) is a well-known adverse event in cancer survivors, the long-term risk of standard low-dose anthracycline has not yet been reported. This study aimed to investigate the long-term effects of standard anthracycline on late CHF in...
Autores principales: | Chung, Il Yong, Lee, Jong Won, Moon, Hyeong-Gon, Shin, Kyung Hwan, Han, Wonshik, Son, Byung Ho, Ahn, Sei-Hyun, Noh, Dong-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414012/ https://www.ncbi.nlm.nih.gov/pubmed/32771950 http://dx.doi.org/10.1016/j.breast.2020.07.006 |
Ejemplares similares
-
Strategies to Prevent Anthracycline-Related Congestive Heart Failure in Survivors of Childhood Cancer
por: Armenian, Saro H., et al.
Publicado: (2012) -
The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012) -
Adherence to Guidelines for Cancer Survivors and Health-Related Quality of Life among Korean Breast Cancer Survivors
por: Song, Sihan, et al.
Publicado: (2015) -
Perspective Insight into Future Potential Fusion Gene Transcript Biomarker Candidates in Breast Cancer
por: Kim, Ryong Nam, et al.
Publicado: (2018) -
Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Han, Ahram, et al.
Publicado: (2013)